KRN2

• UNSPSC Description:

  KRN2 is a selective inhibitor of nuclear factor of activated T cells (NFAT5), with an IC50 of 100 nM. KRN2 has potential to treat NFAT5-mediated Chronic Arthritis[1].

• Target Antigen:

  Nuclear Factor of activated T Cells (NFAT)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/KRN2.html

• Purity:

  98.04

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C(CC6=CC=CC=C6F)=C2C=C1.[Cl-]

• Molecular Weight:

  479.93

• References & Citations:

  [1]Han EJ, et al. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine. 2017 Apr;18:261-273.J Immunol. 2021 Jun 1;206(11):2652-2667.|J Immunol. 2021 Jun 1;206(11):2652-2667.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  248260-75-5